Psychedelic-assisted therapy: An overview for the internist

This good, general Cleveland Clinic Journal of Medicine article comments: “Psychedelic-assisted therapy may be a potentially significant medical advance, offering the possibility of durable therapeutic benefits with rapid onset for some patients with PTSD and depression following only a small number of psychedelic treatments. No psychedelic is currently FDA approved, but psilocybin could possibly gain approval in less than 2 years. If approved, it may be the first of many psychedelics to rejoin psychiatrists’ armamentarium over the next decade. However, we have much to learn about optimizing these treatments in clinical settings and real-world patient populations.”

For more psychedelic news and research, visit the psychedelic health professional network homepage.